Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturin...(ufacturing the lack of market acceptance...)

Date:2/21/2008

ufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Forward Looking Statement for PDL: This press release contains forward-looking statements, including regarding the expected closing of PDL's sale of manufacturing assets to Genmab which involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. The consummation of the sale of assets could be adversely impacted or prevented by failure to satisfy closing conditions, or regulatory delays. Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at http://www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, eve
'/>"/>

SOURCE Genmab A/S Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Medarex Announces Completion of Sale of Shares in Genmab A/S
2. Genmabs Financial Calendar for 2008
3. Genmab Reaches Milestones in Ofatumumab Collaboration
4. Genmab Announces HuMax-CD32b Pre-Clinical Program
5. Roche Files IND for Second Genmab Antibody
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
10. Genmab Announces Results for the First Nine Months of 2007
11. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche